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Mycophenolate mofetil (MMF) was developed with cy-
closporine as a fixed-dose immunosuppressant. More
recent data indicate a relationship between mycophe-
nolic acid (MPA) exposure in individuals and clinical
endpoints of rejection and toxicity. This 2-year, open-
label, randomized, multicenter trial compared the ef-
ficacy and safety of concentration-controlled MMF
(MMFCC) dosing with a fixed-dose regimen in 720 kid-
ney recipients. Patients received either (A) MMFCC and
reduced-level calcineurin inhibitor (MMFCC/CNIRL); (B)
MMFCC and standard-level CNI (MMFCC/CNISL); or (C)
fixed-dose MMF and CNISL (MMFFD/CNISL). Antibody
induction and steroid use were according to center
practice. The primary endpoint was noninferiority (a =
0.05) of group A versus group C for treatment fail-
ure (including biopsy-proven acute rejection [BPAR],
graft loss and death) at 1 year. Although mean CNI
trough levels in group A did not reach the prespeci-
fied targets, they were statistically lower than those in
groups B and C (p ≤ 0.01 for each comparison). BPAR
rates (8.5%) were low across groups. Group A had 19%
fewer treatment failures (23% vs. 28%, p = 0.18). MMF
doses were highest (p < 0.05), with withdrawals for
adverse events the fewest (p = 0.02), in group A. Of
the 80% of subjects taking tacrolimus (Tac), those with
higher MPA exposure had significantly less rejection
(p < 0.001) and diarrhea correlated with Tac, but not
with MPA levels. Thus, MMFCC with low-dose CNI re-
sulted in outcomes not inferior to those with standard
CNI exposure and MMFFD, indicating potential utility
of MMFCC in CNI-sparing regimens.
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Introduction
Although modern immunosuppression in kidney transplan-
tation has led to significant reductions in allograft rejection,
drug-specific complications (including new-onset diabetes
mellitus, hyperlipidemia and hypertension) remain a seri-
ous concern (1). In addition, cyclosporine and tacrolimus,
calcineurin inhibitors (CNI) on which most protocols are
based, are nephrotoxic (2). Nankivell et al. (3) suggest that
histopathologic changes characteristic of chronic allograft
nephropathy are virtually universal in renal allografts after
10 years of CNI maintenance, although this viewpoint is
not universally accepted.
Recent studies indicate immunosuppressive regimens that
include mycophenolate mofetil (MMF) may attenuate CNI-
associated histopathologic changes and decline in renal
function (1,4,5). MMF as a maintenance immunosuppres-
sant has not been associated with short- or long-term neg-
ative effects on renal function, lipid and carbohydrate lev-
els or blood pressure, sequelae that can affect graft and/or
patient survival (6). When used in combination with cy-
closporine, MMF was associated with less chronic allo-
graft nephropathy than azathioprine (7) and significantly
improved renal function in patients with existing chronic
allograft nephropathy (8). In a retrospective study of 66 774
renal allograft recipients receiving CNI maintenance, MMF
(compared to azathioprine) decreased the relative risk of
chronic allograft failure by 27% (p = 0.001) (9), an outcome
consistent with the more recently published histologic find-
ings of Nankivell and colleagues (10).
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Fixed-dose administration of MMF, typically 2 g/day
in adults, is the standard regimen employed in re-
nal transplantation. This dosing regimen, established in
cyclosporine-treated patients, was validated in several
large clinical trials (11–13) and was shown in the recent Effi-
cacy Limiting Toxicity Elimination (ELITE)-Symphony Study
(14) to provide renal function and graft survival benefits
over other regimens when combined with daclizumab
induction and corticosteroid/low-dose tacrolimus mainte-
nance. Mycophenolic acid (MPA) is the active metabolite
of MMF; there are known to be wide ranges in MPA
exposure between patients receiving identical doses of
MMF (15). The physiological basis underlying these differ-
ences is not well established, although a variety of po-
tential contributing factors (specific ethnic status, renal
and liver function and concurrent medications) have been
identified (16). This interpatient variability has fueled an in-
creasing interest in evaluating the utility of MPA exposure
monitoring in clinical transplantation. In several studies,
MPA area under the concentration–time curve (AUC) has
been inversely correlated with the risk of an acute rejec-
tion episode in both renal and cardiac transplant recipients
(17–21) with overexposure thought to increase the risk of
infection and malignancy (22,23). APOMYGRE (24) was a
12-month study in which kidney transplant recipients on
cyclosporine were randomized to fixed-dose MMF or to a
concentration-controlled dose based on MPA AUC. Sub-
jects in the concentration-controlled group demonstrated
significantly less treatment failure (29% vs. 48%; p = 0.03)
and biopsy-proven acute rejection (BPAR) (8% vs. 25%; p =
0.01) than controls, but little difference in infectious compli-
cations. In contrast, another recently published multicenter
study found no advantage associated with concentration-
controlled dosing of MMF (25), noting an overlap of MPA
exposure among treatment groups and reluctance of in-
vestigators to implement early MMF dose adjustments
required to achieve target MPA AUC exposure. The effect
of concentration-controlled dosing of MMF in conjunction
with CNI minimization is unknown.
Although limited (abbreviated) MPA AUC sampling to esti-
mate full interdose AUC has been found to be useful (6,26–
28), it can be labor intensive and cumbersome. Predose (or
trough) level monitoring of tacrolimus and cyclosporine is
common in clinical practice; a similar approach to MPA
monitoring could be easily implemented. However, while
MPA trough levels have been reported to be good and prac-
tical surrogates for MPA AUC, their utility has not been
tested in large trials. Existing studies have been limited
to relatively small numbers of patients and usually in the
setting of cyclosporine coadministration (6).
The Opticept R© trial compared three different dosing regi-
mens, including both fixed and monitored dosing of MMF,
as well as standard and reduced levels of CNIs, to bet-
ter define the utility of trough level-based concentration-
controlled regimens of MMF in facilitating a CNI-sparing
regimen in clinical kidney transplantation.
Figure 1: Trial design and calcineurin inhibitor (CNI) dose ad-
justment by target trough level. MMFCC/CNIRL = controlled-
concentration mycophenolate mofetil (MMF) with reduced-level
CNI dosing; MMFCC/CNISL = MMFCC with standard concentra-
tions of CNIs; and MMFFD/CNISL = fixed-dose MMF with CNISL.
CsA = cyclosporine; post-tx = posttransplant; TAC = tacrolimus.
Methods
Details of the methods are provided in Appendix S1.
Study design
This 2-year, open-label, prospective, randomized, controlled trial was con-
ducted at 51 centers in the United States. Recipients of a single (first or
second) renal allograft from living (related or unrelated) or deceased donors
were eligible for enrollment. The study protocol was reviewed and approved
by the institutional review board at each study site and was conducted in
full conformance with the principles of the Declaration of Helsinki. All study
participants provided signed informed consent prior to randomization. The
study is listed on www.clinicaltrials.gov (NCT00087581).
Randomization and treatment
Patients entered the study within 24 h of transplantation. Eligible subjects
were allocated sequentially in order of their enrollment to one of three
treatment groups in a 1:1:1 ratio (Figure 1). Randomization was balanced
within each center and stratified by CNI (tacrolimus or cyclosporine).
Each treatment group received one of the following regimens: group A,
concentration-controlled MMF with reduced CNI levels (MMFCC/CNIRL);
group B, concentration-controlled MMF with standard CNI administration
levels (MMFCC/CNISL); and group C, fixed-dose MMF with standard CNI
administration levels (MMFFD/CNISL). The target blood levels of tacrolimus
or cyclosporine were as depicted in Figure 1. The initial dose of oral or intra-
venous MMF, to be administered within 24 h following transplantation, was
at least 1 g twice daily for adults and 600 mg/m2 twice daily for pediatric
patients. For patients in the MMFCC groups (groups A and B), the dose
was adjusted to achieve whole blood MPA trough levels of ≥ 1.3 lg/mL
if receiving cyclosporine and of ≥ 1.9 lg/mL if receiving tacrolimus (6),
with the adjusted dose not exceeding 4 g/day regardless of trough level.
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Table 1: Baseline demographics and clinical characteristics of patients and donors
MMFCC/CNIRL MMFCC/CNISL MMFFD/CNISL
Group A Group B Group C
Characteristic (N = 243) (N = 237) (N = 240)
Gender, n (%)
Male 163 (67.1) 159 (67) 163 (67.9)
Female 80 (32.9) 78 (32.9) 77 (32.1)
Age (years), mean (SD) 48.3 (12.8) 48.8 (13.6) 49.6 (13.2)
Race, N (%)
Caucasian 160 (65.8) 168 (70.9) 167 (69.6)
African American 65 (26.7) 58 (24.5) 62 (25.8)
Other 18 (7.4) 11 (4.6) 11 (4.6)
Original kidney disease, N (%)
Diabetes mellitus 64 (26.3) 64 (27.0) 54 (22.5)
Hypertension 56 (23.0) 51 (21.5) 64 (26.7)
Glomerulonephritis 51 (21.0) 55 (23.2) 58 (24.2)
IgA nephropathy 18 (7.4) 10 (4.2) 13 (5.4)
Focal glomerulosclerosis 18 (7.4) 21 (8.9) 21 (8.8)
Other or uncertain 36 (14.8) 36 (15.2) 30 (12.5)
Donor source, N (%)
Deceased 119 (49.0) 118 (49.8) 124 (51.7)
Living related 73 (30.0) 72 (30.4) 61 (25.4)
Living unrelated 48 (19.8) 46 (19.4) 54 (22.5)
Panel reactive antibody levels ≥20%, N (%) 16 (6.6) 20 (8.4) 17 (7.1)
HLA mismatches, total, N (%)
0 27 (11.1) 21 (8.9) 26 (10.8)
1–3 98 (40.3) 87 (36.7) 63 (26.3)
4–6 113 (46.5) 123 (51.9) 144 (60.0)
Unknown 0 (0.0) 2 (0.8) 1 (0.4)
Baseline eGFR (mL/min), mean (SD) 67.5 (19.6) 67.1 (18.4) 65.6 (19.3)
Patients receiving induction therapy, N (%) 182 (75) 178 (75) 181 (75)
Antithymocyte globulin 108 (44) 100 (42) 103 (43)
Basiliximab 50 (21) 55 (23) 52 (22)
Daclizumab 24 (10) 25 (11) 27 (11)
Patients receiving corticosteroids, N (%)
Week 1 228 (93.8) 228 (96.2) 231 (96.3)
Patients receiving CMV prophylaxis, N (%) 111 (45.7) 120 (50.6) 107 (44.6)
CC = concentration controlled; CMV = cytomegalovirus; CNI = calcineurin inhibitor; eGFR = estimated glomerular filtration rate; FD =
fixed dose; HLA = human leukocyte antigen; MMF = mycophenolate mofetil; N = number; RL = reduced level; SD = standard deviation;
SL = standard level.
These levels were selected as an acceptable balance between underdosing
and overdosing based on an exploratory reanalyses of prior MPA exposure
data in renal transplant patients receiving cyclosporine (18) or tacrolimus
(29). Essentially, the target trough level is higher when MMF is adminis-
tered with tacrolimus because a greater proportion of the MPA exposure in
tacrolimus-treated patients is in the latter part of the dosing interval due to
greater enterohepatic recirculation (6). For patients experiencing leukopenia
or gastrointestinal toxicity, MMF dose reductions were managed according
to a defined protocol and were guided by the clinical severity and course
of the adverse event. Induction therapy, corticosteroids and prophylaxis for
opportunistic infections were administered according to center practice.
Study outcomes assessments and endpoints
Patients returned on days 3, 10 and 30 and at months 2, 3, 6, 9, 12 and
20–24 for routine clinical and laboratory evaluations, determination of MPA
and CNI trough levels and reporting of adverse events. MMF doses were
adjusted based on the trough levels although abbreviated AUCs were also
determined during the trial. Abbreviated AUCs were determined by sam-
pling at three time points over 2 h (0, 30 and 120 min) in fasted patients on
days 3, 10 and 30 and months 3, 6 and 12, but were not made available to
investigators.
The primary efficacy endpoint at 12 months posttransplant was the propor-
tion of patients experiencing treatment failure, defined as any of the fol-
lowing: BPAR, graft loss, death, lost to follow-up or withdrawal of consent.
The coprimary endpoint was the change in renal function from baseline
assessed by estimated glomerular filtration rate (eGFR) at 12 months calcu-
lated using the Nankivell equation (30). The secondary endpoints included
(for each treatment group) (i) the proportion of patients experiencing treat-
ment failure within 24 months posttransplant; (ii) the proportion of patients
experiencing BPAR; (iii) the proportion of patients treated for acute rejection
(presumptive acute rejection) within 12–24 months posttransplant; (iv) the
number of BPAR episodes per patient at 12 and 24 months posttransplant;
(v) the time to first BPAR episode at 12 and 24 months posttransplant; (vi)
the proportion of patients who died had a graft loss or discontinued MMF
therapy within 12–24 months; and (vii) the time to treatment failure.
The diagnosis of BPAR was confirmed histologically using the Banff 97
classification criteria (31). Graft loss was defined as the initiation of chronic
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Table 2: Mean daily dose of mycophenolate mofetil (MMF)
MMFCC/CNIRL MMFCC/CNISL MMFFD/CNISL
Group A Group B Group C
MMF (mg) Cyclosporine Tacrolimus Cyclosporine Tacrolimus Cyclosporine Tacrolimus
1– 7 days
Mean 1955.4 1987.8 2032.5 1995.2 1939.2 1958.3
SD 286.26 311.7 263.75 299.27 368.15 339.79
N 40 198 45 187 42 195
8–30 days
Mean 2354.91 2109.22 2194.7 2078.43 2093.8 1947.0
SD 527.45 498.78 463.04 436.24 307.98 367.31
N 37 191 45 185 40 189
31–90 days
Mean 2465.02 2063.72 2318.83 1972.4 2034.8 1862.3
SD 700.54 567.6 566.56 605.4 313.95 425.34
N 36 184 44 177 38 183
91–180 days
Mean 2229.11 1971.62,4 2217.73 1812.9 1872.4 1700.5
SD 977.97 629.57 772.57 670.2 379.5 503.51
N 33 175 42 162 37 168
181–365 days
Mean 2024.4 1896.82,4 1913.8 1723.5 1833.9 1662.7
SD 895.32 606.36 736.16 668.09 459.09 474.48
N 33 168 39 143 33 152
CC = concentration controlled; CNI = calcineurin inhibitor; FD = fixed dose; N = number; RL = reduced level; SD = standard deviation;
SL = standard level.
1P <0.05 for group A versus group C.
2P <0.008 for group A versus group C.
3P <0.05 for group B versus group C.
4P<0.02 for group A versus group B.
dialysis (at least 6 consecutive weeks in duration), transplant nephrectomy,
retransplantation or death with a functioning graft.
Safety endpoints included (i) all adverse events, defined as any medical
occurrence whether related to treatment or not and including worsening
of preexisting conditions; (ii) opportunistic infections; (iii) malignancies; (iv)
abnormal laboratory findings; and (v) renal function as assessed by eGFR
at 3, 6 and 24 months.
Results
Patient enrollment and baseline characteristics
The study was conducted between June 2004 and
September 2007. A total of 720 patients were randomized
(intent-to-treat population); the safety population included
709 patients. Approximately 80% of patients in each group
received tacrolimus. Three quarters of participants in each
treatment group received induction therapy; overall, an-
tithymocyte globulin (43%) was used more frequently than
basiliximab (22%) or daclizumab (11%) (Table 1).
Overall, 483/720 (67%) patients completed 12 months of
treatment on protocol. Study withdrawal occurred less of-
ten among group A patients (63/243, 26%) compared with
87/237, 37% and 87/240, 36% in groups B and C, respec-
tively (p = 0.02). Although the majority of discontinuations
were unrelated to safety issues, there were also signifi-
cantly fewer withdrawals due to adverse events in group A
(18/243, 7.4%) versus group B (34/237, 14.3%) and group
C (34/240, 14.2%; p = 0.02). After 12 months, 77% of pa-
tients in group A remained on MMF versus 66% of patients
in group B and 68% in group C.
Immunosuppressant doses and exposure
After the first week posttransplant through day 180, the
mean daily dose of MMF received by subjects in group
A (MMFCC/CNIRL) was significantly higher than in those
receiving MMFFD/CNISL (group C) for either cyclosporine
or tacrolimus (Table 2). For patients receiving tacrolimus
(but not among those on cyclosporine), the MMF dose in
the MMFCC/CNIRL treatment group was also significantly
higher than in the MMFCC/CNISL group after the first week
of therapy.
A summary of MPA trough concentrations by CNI type is
shown in Table 3. Mean MPA trough levels exceeded the
target at and beyond day 10 for those receiving tacrolimus
(but only after 2 months for cyclosporine-treated patients)
and generally were maintained throughout the study. The
mean abbreviated MPA AUC increased during the first
3 months of treatment and then stabilized with MPA ex-
posure significantly greater in the tacrolimus-treated than
in the cyclosporine-treated patients. By 6 months, MPA
1610 American Journal of Transplantation 2009; 9: 1607–1619
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































exposures equalized for the cyclosporine- and tacrolimus-
treated patients in the two concentration-controlled groups
but not in the fixed-dose group (Table 3). Trends in the dose-
corrected MPA AUC values were similar. At 12 months,
there was a positive correlation between abbreviated MPA
AUC and trough concentrations overall, and the correlation
was stronger for patients receiving tacrolimus (Figure 2A)
than for those treated with cyclosporine (Figure 2B; r2 =
0.6864; p < 0.0001 vs. r2 = 0.3288; p < 0.0001, respec-
tively).
As per protocol by month 3 and thereafter, the mean trough
level of tacrolimus in the MMFCC/CNIRL group (group A),
though not as low as originally targeted, was statistically
lower (p ≤ 0.01) than in the other two treatment groups
(Figure 3). Although the trough levels of cyclosporine were
also numerically lower in group A than in the other two
treatment groups, the sample size was too small for sta-
tistical analysis.
Efficacy
The number and percentage of patients with treatment
failure at 12 months posttransplant were 55/243 (22.6%)
for the MMFCC/CNIRL group (group A), 67/237 (28.3%) for
group B and 67/240 (27.9%) for group C (Table 4). Group A
had a 5.3% lower rate of treatment failure (90% confidence
interval [CI]: −11.8, 1.3; p = 0.18), a 19% reduction, con-
firming noninferiority of outcomes in this treatment group.
There was also no significant difference in treatment failure
among the groups stratified by CNI type (data not shown).
Deaths were infrequent across the groups. Diabetes at
baseline was significantly associated with time to death
(risk ratio = 2.46; 95% CI: 1.0, 6.0; p = 0.05).
The baseline eGFR (30 days posttransplant) was similar
across groups. At 12 months, patients in group A had a
12.3% increase in eGFR from baseline compared to a 5.4%
increase in group B and an 8.2% increase in group C. When
analyzed by CNI, the mean percentage increase in eGFR
for those receiving cyclosporine in the MMFCC/CNIRL group
(group A) was greater than in the MMFCC/CNISL group (p =
0.05) (Figure 4), but similar to that in group C (p = 0.11).
The results of the secondary endpoints are provided in
Table 5. A total of 61/720 (8.5%) participants had a BPAR
episode during the 12 months of the study with a majority
of rejection episodes occurring within the first 6 months
posttransplant. Across groups, more patients receiving cy-
closporine (16/130, 12.3%) experienced BPAR than those
receiving tacrolimus (45/590, 7.6%). Although the percent-
age of patients with BPAR was somewhat lower in group
A than in group C, the difference was not significant (p =
0.17). In the tacrolimus-treated group, dose-uncorrected
MPA trough levels had a significant impact on the time
to first BPAR at 6 and 12 months (risk ratio = 0.322 [p <
0.0001] and 0.390 [p < 0.0001], respectively), as did the ab-
breviated MPA AUC values (risk ratio = 0.933 [p < 0.0002]
1612 American Journal of Transplantation 2009; 9: 1607–1619
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Figure 2: Linear regression anal-
ysis of the estimated mycophe-
nolic acid (MPA) area under the
concentration–time curve (AUC) ver-
sus trough in patients receiving (A)
tacrolimus and (B) cyclosporine.
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Figure 3: Tacrolimus trough levels.
SEM = standard error of the mean.
∗p ≤ 0.0003 for group A versus group
C; p ≤ 0.01 for group A versus group B.
and 0.926 [p < 0.0001], respectively). MPA trough con-
centrations ≥1.6 lg/mL were associated with a longer
time to first BPAR episode in tacrolimus-treated patients
from all three groups (Figure 5). For these tacrolimus pa-
tients, higher MPA trough concentrations or higher abbre-
viated MPA AUC values were associated with a lower
risk of rejection. The number of cyclosporine-treated pa-
tients was too small for similar analyses. Similarly, the
heterogeneity of antibody induction precluded meaning-
ful analysis of its impact on the risk of rejection (data not
shown).
Table 4: Treatment failure within 12 months posttransplant by (A) treatment group and (B) calcineurin inhibitor (CNI) type, N (%)
MMFCC/CNIRL MMFCC/CNISL MMFFD/CNISL
Group A Group B Group C
(N = 243) (N = 237) (N = 240)
(A) Treatment failure within 12-months posttransplant by treatment group, N (%)
Treatment failure1 55 (22.6) 67 (28.3) 67 (27.9)
90% CI for treatment failure 17.5, 28.4 22.6, 34.5 22.3, 34.1
Reason for treatment failure
Biopsy-proven acute rejection 15 (6.2) 23 (9.7) 23 (9.6)
Graft loss 5 (2.1) 4 (1.7) 4 (1.7)
Death 4 (1.6) 2 (0.8) 6 (2.5)
Lost to follow-up or discontinued 15 (6.2) 18 (7.6) 22 (9.2)
Withdrew consent 16 (6.6) 20 (8.4) 12 (5.0)
CsA (N = 41) TAC (N = 202) CsA (N = 47) TAC (N = 190) CsA (N = 42) TAC (N = 198)
(B) Treatment failure within 12 months posttransplant by CNI type, N (%)
Treatment failure2 8 (19.5) 47 (23.3) 15 (31.9) 52 (27.4) 13 (31.0) 54 (27.3)
95% CI 8.8, 34.9 17.6, 29.7 19.1, 47.1 21.2, 34.3 17.6, 47.1 21.2, 34.0
CC = concentration controlled; CI = confidence interval; CsA = cyclosporine; FD = fixed dose; MMF = mycophenolate mofetil; N =
number; RL = reduced level; SL = standard level; TAC = tacrolimus.
Events are mutually exclusive because only the first event was counted for each patient.
Ninety-five percent CI calculated using the exact method.
p-values are from the Cochran–Mantel–Haenszel test comparing the treatment groups and stratified by CNI type.
1p = 0.1825 for group A versus group C; 0.8683 for group B versus group C; and 0.1302 for group A versus group B.
2For cyclosporine, p = 0.23 for group A versus group C; 0.92 for group B versus group C; and 0.19 for group A versus group B; for
tacrolimus p = 0.36 for group A versus group C; 0.98 for group B versus group C; and 0.35 for group A versus group B.
Limited data analyses were conducted at 20–24 months,
with approximately two-thirds of patients having final as-
sessments. These data did not differ significantly from the
12-month data in terms of eGFR, BPAR or treatment fail-
ure. At 20–24 months, treatment failure had occurred in
30.5% (74/243), 40.5% (96/237) and 35.0% (84/240) of
patients in groups A, B and C, respectively (p = 0.02 for
the comparison between groups A and B). The proportion
of patients with BPAR was 6.6% (16/243), 11.0% (26/237)
and 10.0% (24/240) in groups A, B and C, respectively,
with no significant differences among groups.
1614 American Journal of Transplantation 2009; 9: 1607–1619






































































Figure 4: Mean change in estimated
glomerular filtration rate (eGFR;
Nankivell) stratified by calcineurin
inhibitor (CNI) from baseline to 12
months. Cyclosporine: MMFCC/CNIRL
versus MMFFD/CNISL, p = 0.11; and
MMFCC/CNIRL versus MMFCC/CNISL,
p < 0.05. Tacrolimus: MMFCC/CNIRL
versus MMFFD/CNISL, p = 0.67; and
MMFCC/CNIRL versus MMFCC/CNISL,
p = 0.35. MMFCC/CNIRL = controlled-
concentration of mycophenolate
mofetil (MMF) with reduced level of
CNI dosing; MMFCC/CNISL = MMFCC
with standard concentrations of CNIs;
and MMFFD/CNISL = fixed dose MMF
with CNISL; SD = standard deviation.
Safety outcomes
The occurrence of adverse events was similar across
treatment groups. Common adverse events are listed by
frequency in Table 6. Diarrhea was the most frequent, oc-
curring in approximately 40% of participants in all treat-
ment groups, but notably more common in patients receiv-
ing tacrolimus (269/582, 46%) than cyclosporine (27/127,
21%; p < 0.001). Within the first 90 days posttransplant,
243/720 (34%) of the total patients, 18/130 (14%) receiving
cyclosporine and 225/590 (38%) receiving tacrolimus had
diarrhea. Tacrolimus trough levels appeared to be higher
in patients with diarrhea (N = 225) compared to patients
without diarrhea (N = 365). A Cox proportional hazards
model indicated that CNI type had a significant impact on
the time to a first episode of diarrhea within 90 days post-
transplant, with a risk ratio of 0.273 for cyclosporine ver-
sus tacrolimus (p < 0.0001). For patients taking tacrolimus,
those with higher tacrolimus trough levels drawn prior to
Table 5: Secondary efficacy endpoints at 12 months
MMFCC/CNIRL MMFCC/CNISL MMFFD/CNISL
Group A Group B Group C
Endpoint (N = 243) (N = 237) (N = 240) p-Value
Biopsy-proven acute rejection, N (%) 15 (6.2) 23 (9.7) 23 (9.6) 0.171
Number of episodes of biopsy-proven 0.352
acute rejection per patient
0 228 (93.8) 214 (90.3) 217 (90.4)
1 13 (5.3) 21 (8.9) 21 (8.8)
2 or more 2 (0.8) 2 (0.8) 2 (0.8)
Presumptive acute rejection, N (%)3 16 (6.6) 26 (11.0) 25 (10.4) 0.131
95% CI 3.8, 10.5 7.3, 15.7 6.9, 15.0
Unknown, N 36 42 39
Time to treatment failure, mean days4 265.9 296.5 290.0 0.221
CC = concentration controlled; CI = confidence interval; CNI = calcineurin inhibitor; FD = fixed dose; MMF = mycophenolate mofetil;
N = number; RL = reduced level; SL = standard level.
1Comparison between MMFCC/CNIRL and MMFFD/CNISL.
2Overall treatment effect p-value from the Poisson regression model with treatment and CNI type as factors.
3Presumptive rejections include patients treated for rejections but no biopsy performed and all biopsy-proven acute rejections.
4Kaplan–Meier product limit estimates, mean days since first trial medication.
the occurrence of diarrhea were at a greater risk for ex-
periencing diarrhea (risk ratio = 1.049; p = 0.004). Across
all patients, MPA trough levels were not related to diar-
rhea (p = 0.5125). Overall, the incidence of new-onset di-
abetes mellitus was higher in those receiving tacrolimus
compared to those receiving cyclosporine (73/582 [12.5%]
vs. 5/127 [3.9%], respectively; p = 0.004).
At 12 months, 9–12% of patients in all three groups
experienced one or more opportunistic infections, most
commonly cytomegalovirus (CMV). Overall, 12/238 (5.0%),
14/233 (6.0%) and 18/238 (7.6%) patients had CMV infec-
tions, primarily viremia only, in groups A, B and C, respec-
tively. BK virus infection occurred in 4/238 (1.7%), 7/233
(3.0%) and 8/238 (3.4%) and BK virus nephropathy in 0/238
(0%), 4/233 (1.7%) and 4/238 (1.7%) patients in groups A,
B and C, respectively. No difference was seen between
CNI types with regard to either CMV or BK virus infection,
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Figure 5: Mycophenolic acid
(MPA) exposure and time to first
biopsy-proven acute rejection
(BPAR) episode. Cox proportional
hazards model estimate with the
abbreviated MPA area under the
concentration–time curve, baseline
hypertension/diabetes and treatment
effect (groups A versus C, groups B
versus C) as covariates. Cutoff point
of ≥1.6 lg/mL was based on receiver
operating characteristic analysis of the
study data.
and no significant differences were observed in the risk of
BK virus infection for those with MPA trough levels ≥ 1.6
lg/mL compared to those with levels < 1.6 lg/mL.
Discussion
The principal finding of this trial is that a maintenance
immunosuppressive regimen employing concentration-
controlled dosing of MMF in combination with a low-dose
CNI was not inferior to a fixed-dose regimen of MMF with
respect to treatment failure in renal transplant patients.
In addition, these data confirm previously described differ-
ences in MPA exposure for patients receiving tacrolimus
versus cyclosporine, with the former achieving target levels
Table 6: Selected adverse events reported postrandomization, N (%)1
MMFCC/CNIRL MMFCC/CNISL MMFFD/CNISL
Group A (N = 238) Group B (N = 233) Group C (N = 238)
CsA TAC CsA TAC CsA TAC
(N = 40) (N = 198) (N = 45) (N = 188) (N = 42) (N = 196)
Diarrhea2 5 (13) 93 (47) 16 (36) 86 (46) 6 (14) 90 (46)
Leukopenia 7 (18) 50 (25) 12 (27) 48 (26) 11 (26) 58 (30)
Hypertension 7 (18) 47 (24) 8 (18) 44 (23) 11 (26) 39 (20)
Hyperlipidemia 35 (85) 158 (78) 38 (81) 139 (73) 32 (76) 148 (75)
Opportunistic infections3 5 (13) 17 (9) 7 (16) 23 (12) 3 (7) 22 (11)
Diabetes mellitus4 2 (5) 32 (16) 2 (4) 23 (12) 1 (2) 18 (9)
Malignancies5 2 (5) 3 (2) 0 (0) 6 (3) 1 (2) 6 (3)
CC = concentration controlled; CNI = calcineurin inhibitor; CsA = cyclosporine; FD = fixed dose; MMF = mycophenolate mofetil; N =
number; RL = reduced level; SL = standard level; TAC = tacrolimus.
1Safety population included patients who received ≥1 dose of the study medication.
2p < 0.0001 for TAC versus CsA stratified by treatment groups and the impact of TAC versus CsA on time to first episode within 90 days
posttransplant.
3Patients with at least one opportunistic infection.
4p < 0.05 for TAC versus CsA stratified by treatment groups.
5Malignancies counting patients only.
substantially earlier and more consistently after transplan-
tation. Finally, as in previous trials, despite the absence
of overall statistical differences among treatment groups,
there was a strong statistical relationship between MPA ex-
posure and the lower risk of rejection in tacrolimus-treated
patients, as well as trends suggesting less rejection, better
renal function and fewer adverse events in the low-dose
CNI group with concentration-controlled MMF dosing.
The overall rates of BPAR were notably low across groups,
especially when compared with other studies employ-
ing targeted dosing of MMF in combination with cy-
closporine (the APOMYGRE study) (24) or standard-dose
MMF in combination with low-dose tacrolimus (the ELITE-
Symphony study) (14). The rate of BPAR in patients
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receiving concentration-controlled MMF in this trial was
approximately half that of subjects similarly treated in the
ELITE-Symphony study (daclizumab induction, fixed-dose
MMF and corticosteroids) (14) despite comparably low ex-
posure to tacrolimus. The fact that antithymocyte globulin
was used in >40% of patients in the present study could
have contributed to the more positive outcomes. Still, in
the present trial, the impact of induction therapy on BPAR
appeared minimal in the patients receiving tacrolimus, par-
ticularly in the MMF concentration-controlled groups. Al-
though BPAR rates tended to be higher in patients receiv-
ing cyclosporine, the number of patients receiving this CNI
was too small for a meaningful comparison.
With a starting MMF dose of 2 g/day, MPA exposure
was significantly (25–35%) greater in tacrolimus-treated
than in cyclosporine-treated patients by day 10, and in
the fixed-dose cohort this difference persisted through-
out. This is thought to be due to the inhibition of the
enterohepatic circulation of MPA by cyclosporine (32). Cer-
tainly, the increased early exposure to MPA that accom-
panies tacrolimus use may contribute to a lesser risk
of rejection in patients so treated. In the concentration-
controlled groups, MPA exposure did not vary by CNI
after the third month posttransplant. The concentration-
controlled groups received significantly higher doses of
MMF regardless of CNI type; these differences in dose
resulted in higher MPA AUC than in the fixed-dose MMF
group receiving standard levels of cyclosporine, but com-
parable differences were not seen in those receiving
tacrolimus.
The change from baseline in eGFR between the groups
was numerically superior in the MMFCC/CNIRL group but
was not statistically significant; however, the difference
in eGFR from baseline for cyclosporine-treated patients in
the reduced CNI level group was significant. Since most of
the patients in the trial received tacrolimus, the presumed
superiority of tacrolimus to cyclosporine in terms of re-
nal function and immunosuppressive efficacy may have
masked any additional benefits of tailoring MMF dosing
in the group as a whole. Additionally, the failure to achieve
CNI levels that differentiated treatment groups as distinctly
as originally targeted may have contributed to the similarity
in eGFR over time. It is also notable that MPA exposure in
tacrolimus-treated patients was identical at all time points
with or without monitored dosing. These findings, along
with those of the APOMYGRE study (24), indicate that
MPA monitoring and a CNI-reduction strategy may be par-
ticularly useful in cyclosporine-treated patients. However,
as demonstrated by the relatively poor correlation of trough
level with MPA AUC in the cyclosporine-treated patients,
such an approach may require AUC rather than predose
monitoring.
Mean CNI trough levels in group A were not as low as
originally targeted but were still statistically significantly
lower than levels in the other two treatment groups. How-
ever, these between-group differences did not appear to
be clinically significant. Tacrolimus levels in group A were
not low enough to result in a clinical difference between
groups in eGFR. Similarly, reports of adverse events such
as diarrhea, diabetes mellitus and opportunistic infections
were comparable among groups A, B and C.
There are obvious limitations to this trial. First, as in the
Fixed-Dose Concentration-Controlled Trial (25), what ap-
peared to be a reluctance to adhere to target MPA trough
levels resulted in a wide variability among doses, dose
changes and exposure among subjects, with little differen-
tiation among treatment groups in MPA exposure. Second,
the attempt to facilitate broad enrollment by allowing inves-
tigators the choice of induction and CNI agents resulted in
a great deal of heterogeneity among the three treatment
groups, making interpretation difficult. This study empha-
sizes the ongoing challenge in designing clinical trials flex-
ible enough to encourage enrollment yet rigorous enough
to result in robust conclusions. Third, the failure to achieve
and maintain target immunosuppressant levels, particu-
larly in the reduced CNI group, may have contributed to
the inability to detect significant differences among groups
in several outcomes, illustrating the complexities of adher-
ence to a study design in which blood-level targets are
predetermined. Indeed, the benefits of MPA monitoring in
the APOMYGRE study (24) emerged from a study with rel-
atively homogenous CNI and induction therapies and spe-
cific MMF dose changes determined by an algorithm rather
than by an investigator choice. Finally, it is possible that any
advantage associated with concentration-controlled dos-
ing of MMF is small enough that all of these factors make
it easy to mask.
So, how is one to interpret Opticept? It is tempting to
focus on data supporting the benefit of concentration-
controlled MMF dosing: a strong correlation between MPA
exposure and the risk of rejection, with trends to bet-
ter renal function, fewer rejection episodes and fewer se-
vere adverse effects. Indeed, if one presumes that lower
CNI levels should result in more adverse immunological
events, a finding of noninferiority in this study might be at-
tributable to the strategy of concentration-controlled dos-
ing. The truth is that most clinicians now use tacrolimus at
doses and levels comparable to those used in group A, and
the majority of tacrolimus-treated patients achieve thera-
peutic MPA exposure with empiric dosing (albeit perhaps
not as quickly). In terms of safety, the ability to admin-
ister more MMF with fewer discontinuations for adverse
events and the relative absence of serious BK disease in
the MMFCC/CNIRL group is intriguing. Perhaps the ben-
efit of tailoring MMF dosing to exposure, particularly in
tacrolimus-treated patients, manifests in a relatively small
number of recipients for whom maintaining appropriate
exposure without overimmunosuppression is critical. Such
an interpretation is consistent with the trends suggestive
of a benefit but not discernable by analysis of broad group
statistics.
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